Avacta Therapeutics (AIM: AVCT) has reported encouraging preclinical results for its experimental cancer treatment AVA6103, demonstrating tumour responses in models resistant to Enhertu, as the company advances its Phase 1

Avacta Therapeutics (AIM: AVCT) will present updated clinical data from its Faridoxorubicin (AVA6000) cancer programme and details of its AVA6103 trial at the European Society for Medical Oncology (ESMO) Congress

Avacta Therapeutics (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share.

Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.

Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.

Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic

Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.

  Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.

Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.

Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and

Accelerated Amortized Payment of Convertible Bond Installment